The battle over the common generic carve-out has made its way to the White House. The Supreme Court has asked the Solicitor General to weigh in on the matter of carve outs. The industry ponders the implications of the pending opinion on pharmaceutical patents as well as the practice of patent law. In this session, points of discussion will include:

• Evaluating the impact of GSK v. Teva, Amarin v. Hikma and their progeny on proving induced infringement
• Analyzing recent court treatment
• Types of evidence to demonstrate inducement
• Pre-launch v. post-launch
• Distinguishing between skinny labels and partial labels
• Explaining the patentability of further medical use inventions
• Strategies for claim drafting in view of these decisions
• Reevaluating claim and label language
• Detailing what every patent owner needs to consider when labeling FDA-approved products
• Best practices for aligning patent claims with the label
• Considerations for multiple approved indications